Rufinamide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Rufinamide. Educational only — not medical advice.
Labeled uses
Rufinamide oral suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
Source: FDA labeling via NIH DailyMed (set a02ca527…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.